Objective: To compare the effects of a lipid emulsion containing medium-chain triglycerides (MCT) and supplemented with atocopherol to a conventional long-chain triglyceride (LCT) emulsion. Design: Randomised double blind study. Setting: Department of Internal Medicine, Antwerp University Hospital. Subjects and interventions: Twenty-four patients with an indication for total parenteral nutrition for a minimum of 10 days were randomly assigned to two groups: group E received as lipid source MCT=LCT (50=50) suplemented with 100 mg DL-atocopherol=day and group C received LCT. Blood samples were analysed at inclusion, after 4 -6 and after 9 -11 days. Results: In group E, serum a-tocopherol doubled from 11.4 AE 6.9 at inclusion to 20.9 AE 7.9 and to 23.8 AE 8.8 mg=ml after 4 and 9 days, respectively, but did not change in group C (P ¼ 0.008). Production of thiobarbituric acid-reacting substances (TBARS) after 120 min incubation with copper decreased from 66 AE 34 at inclusion to 29 AE 25 nmol MDA=mg LDL and VLDL-cholesterol after 4 and to 42 AE 17 after 9 days (P ¼ 0.022 when compared to group C, which underwent no significant changes). Velocity of production of fluorescent products decreased in group E but not in group C (P ¼ 0.026). Conclusions: Supplementation of TPN containing MCT=LCT with 100 mg DL-a-tocopherol=day leads to a doubling in serum atocopherol and to a decrease in the susceptibility of LDL and VLDL to peroxidation in vitro.
Introduction
Intravenous lipid emulsions have been in clinical use for over 25 y and until recently triglycerides derived from soybean were the sole source of parenteral lipid. However, these lipid infusions have been implicated in complications such as impaired function of the clotting and immunological systems (Babineau et al, 1994) as well as increased lipid peroxidation in vivo. Indeed, patients receiving total parenteral nutrition (TPN) have increased levels of some endproducts of lipid peroxidation such as breath alkanes (Lemoyne et al, 1988; Pitkanen et al, 1991) . Since lipid peroxidation has been identified as a major event in degenerative processes such as ageing, atherosclerosis, cancer, inflammatory diseases and diabetes (Pincemail et al, 1996) , serious efforts should be made to prevent it in all clinical situations including parenteral nutrition.
This increased risk of lipid peroxidation can be explained by the presence of several types of risk factors in TPN. First, the underlying disease can lead to both increased production of free radicals and to decreased antioxidant defences. For example, in fat malabsorption and liver dysfunction vitamin E status might already be compromised by decreases in both vitamin E absorption and transport in lipoproteins. Second, the TPN lipid emulsion itself, because of its composition, rich in polyunsaturated fatty acids (PUFA), is prone to peroxidation in vitro (during storage) with consumption of its own antioxidants. As a consequence, the lipid emulsion can be depleted of vitamin E and will even contain peroxidation products. When given intravenously these products will in themselves seed and promote lipid peroxidation in vivo. These processes have been shown to lead to cell damage and have been related to increased morbidity in prematures (Pitkanen et al, 1991; 1992) . Third, although some lipid emulsions derived from soybean are rich in vitamin E, this is present predominantly as the less active b and g forms (92% of the total tocopherol; Vandewoude et al, 1986) . As a consequence, patients on TPN have lower levels of a-tocopherol in plasma, in erythrocytes (Kelly & Sutton, 1989; Hack et al, 1990) and in adipose tissue (Steephen et al, 1991) . In contrast, plasma levels of the b and g forms can even increase during the course of TPN (Kelly & Sutton, 1989) .
In order to counteract the pro-oxidant characteristics of TPN and the tocopherol imbalance in plasma, several authors have recommended that the daily supplements of 10 mg D-a-tocopherol equivalents=day (National Research Council, 1980) should be substantially increased during TPN (Vandewoude et al, 1986; Steephen et al, 1991) . However, there is still no consensus on either the dosage or on the composition of vitamin E to be administered. For example, supplementation with 15 mg a-tocopherol daily corrected the tocopherol imbalance in plasma only partly and did not improve erythrocyte tocopherol concentration at all (Kelly & Sutton, 1989) . When considering higher doses, we have previously shown that supplementation of the lipid emulsion with 100 mg DL-a-tocopherol daily is as efficient as 200 mg daily in doubling serum levels of atocopherol after 1 week of supplementation (De Bosscher et al, 1997) .
Another possible way of decreasing TPN-related lipid peroxidation is to use lipids with lower concentrations of peroxidation-prone polyunsaturated fatty acids by replacing a portion of long chain (LCT) by medium-chain triglycerides (MCT).
In order to investigate these two possibilities of decreasing lipid peroxidation in TPN patients we compared the effects of a MCT=LCT (50=50) lipid emulsion supplemented with DLa-tocopherol (100 mg=day) to a conventional LCT lipid emulsion.
Materials and methods
Patient population and study design Patients for whom TPN was indicated for a period of at least 10 consecutive days were selected to take part in the study after informed consent. Exclusion criteria were: pregnancy, severe disorders of ionic and water balance, coagulation disorders, acute liver dysfunction, acute renal insufficiency, shock, acute thromboembolism, sepsis, haemorragic necrotising pancreatitis, trauma to thorax and liver, pre-existing hypertriglyceridaemia ( > 250 mg=dl or > 2.86 mmol=l) and diabetes mellitus (fasting blood glucose > 200 mg=dl or > 11 mmol=l). All patients received continuous TPN which was administered as an 'All-in-One' mixture, containing 0.25 g N and 30 kcal per kg body weight whereby 50% of the non-protein energy was given as lipids. DL-a-tocopherol (B Braun Medical, NVSA, Diegem, Belgium) . The composition of both lipid regimens is shown in Table 1 . From the data in Table 1 and the vitamin supplements (Cernevit 1 ) given, and taking into account that the biological activities of the natural tocopherols (present in the soybean oil) D-a, D-b and D-g-tocopherol are 1.49, 0.75 and 0.15 IU= mg respectively, and that the synthetic form of DL-atocopherol present in the supplements has an activity of 1.1 IU= mg, we can estimate that group E received about 125 IU and group C 20 IU tocopherol per day.
The experimental protocol was in accord with the Helsinki declaration and was approved by the ethical commis- Since these lipids are derived from natural oils, tocopherol composition varies from batch to batch and the values presented here are taken from Kelly and Sutton (1989) . (D) Natural a-tocopherol (RRR stereoisomer); (DL) synthetic or all-rac form, which is a mixture of eight stereoisomers.
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Analytical methods
Blood samples were taken three times: at inclusion (before starting TPN and in the fasting state), after 4 -6 days and 9 -11 days of TPN, during the infusion. Routine safety blood tests (blood count, urea nitrogen, creatinine, uric acid, glucose, liver enzymes, protein, albumin, total and HDL-cholesterol, sodium, potassium, calcium, parathyroid hormone, iron and TIBC, bilirubin, C-reactive protein and alkaline phosphatase) were analysed daily in the routine laboratory of the clinic. Serum triglycerides were measured by dry chemistry based on hydrolysis of triglycerides and enzymatic measurement of liberated glycerol. Total analytical variability, expressed as coefficient of variation (CV) was 2, 1.9 and 0.9% for total cholesterol, HDL-cholesterol and triglycerides, respectively. LDL-cholesterol was calculated according to the Friedewald equation (Friedewald et al, 1972) . Oxidant -antioxidant balance was evaluated by measuring the concentrations of individual antioxidants and the susceptibility of lipoproteins to oxidative attack in vitro (peroxidation in vitro). Vitamins E and A in serum were measured by HPLC (Shimadzu, Kyoto, Japan) with a reverse-phase C 18 column (Bio-Rad Laboratories, Hercules, CA) with 100% methanol mobile phase) and detection at 292 and 325 nm, respectively, with CVs of 10 and 13%, respectively (Caye-Vaugien et al, 1990) . The susceptibility of low density (LDL) and very low density lipoproteins (VLDL) to copper-catalysed oxidation was measured by isolation of these two groups of lipoproteins (here named non-HDL) from plasma anticoagulated with EDTA, precipitation by dextran sulphate=MgCl 2 and incubation of this suspension (containing 200 mg=ml of cholesterol) with 46 mM CuSO 4 for up to 180 min at 37 C. Electrophoresis of this non-HDL fraction demonstrated that it contained no chylomicrons or other proteins such as apoprotein A or albumin and globulins. Two types of peroxidation products were monitored in parallel: thiobarbituric acid-reactive substances (TBARS) and the fluorescent end-products formed as a consequence of the interaction between TBARS and amino acids in the apoprotein B of the LDL. Aliquots were taken every 30 min for the spectrophotometric measurement of TBARS and fluorescence was monitored continuously at 360 nm excitation and 430 nm emission. Three phases were distinguished during the formation of fluorescence: (1) the lag time (expressed in min), during which fluorescence does not increase significantly -it quantifies the capacity of the antioxidants within the lipoproteins to retard the initiation of oxidation; (2) the slope of the propagation phase, during which fluorescence increases rapidly and which indicates the velocity of oxidative changes in the apo B; and (3) the saturation phase during which fluorescence reaches a plateau and which gives an estimate of the total amount of lipid oxidized (Zhang et al, 1994) . CVs of TBARS and parameters of fluorescence ranged from 3 to 11%.
Statistical analysis
Data was analysed using the SPSS 9.0 package (SPSS Inc., Chicago, IL, USA). Data in the text is expressed as mean AE s.d. The changes over time of the various variables during the course of the study was studied using repeated measures analysis of variance with contrasts referring always to the inclusion values. The differences between the two groups as regards these time-related changes were also analysed. Pvalues < 0.05 were considered as significant.
Results
Patient characteristics at inclusion are shown in Table 2 . In order to correct for the between-group differences concerning routine serum biochemistry (ureum and transaminases) at inclusion, statistical comparisons on the evolution of parameters during the course of the study were always referred to the inclusion values.
The evolution of routine biochemical parameters was not significantly different between the two groups. Figure 1 shows that total cholesterol and LDL-cholesterol did not change during the course of the study in either group. However, HDL-cholesterol decreased in both groups (P ¼ 0.04 for the time-related changes during the course of the study within group E and P ¼ 0.07 within group C), but there was no significant difference in the evolution of the two groups. In contrast, serum triglyceride-derived glycerol increased in group E from 15 AE 7 to 26AE 13 after 4 -6 days TPN and to 29 AE 12 mg=dl after 9 -11 days (P ¼ 0.012 for the within-group change) and decreased in group C from 15 AE 10 to 11 AE 7 and to 11 AE 5 mg=dl (P ¼ 0.038). There was thus a a-Tocopherol supplementation in TPN B Manuel-y-Keenoy et al highly significant difference between the two groups as regards evolution during the course of the study (P ¼ 0.001 for the between-groups comparison). As shown in Figure 2 , in group E serum levels of atocopherol doubled from 11.4 AE 6.9 at inclusion to 20.9 AE 7.9 mg=ml after 4 -6 days TPN (P ¼ 0.027 when compared to the values at inclusion) and to 23.8 AE 8.8 after 9 -11 days (P ¼ 0.008). In group C levels did not change, so that the changes over time during the course of the study were significantly different between the two groups (P ¼ 0.006). When a-tocopherol levels were expressed as mg=mg total serum cholesterol these differences between the two groups were still demonstrated (P ¼ 0.027). Two individuals in group C had inclusion serum a-tocopherol levels indicating deficiency (5 and 4.1mg=ml). These increased to 6.4 and 8.3mg=ml, respectively, after 9 -11 days of parenteral nutrition. Exclusion of these two patients from the analysis did not modify the results.
Susceptibility of lipoproteins to peroxidation in vitro was monitored by subjecting the LDL and VLDL of each patient at each visit to an incubation with copper and measuring the time course of production of TBARS and of fluorescent products. As shown in Figure 3 , TBARS production increases significantly only after 60 min incubation. After an early initiation phase (90 -120 min) it increases linearly (from 120 to 150 min) before reaching the saturation phase (180 min). In contrast, the production of fluorescent products started later than TBARS, the lag time being 98 AE 29 min in these patients. Indeed the factors affecting these two peroxidation parameters also differed. Ninety minute-TBARS production was related to LDL-cholesterol (r ¼ 0.51, P ¼ 0.013), whereas lag time of fluorescence correlated with serum a-tocopherol (r ¼ 0.66, P < 0.0001).
In group E, TBARS production after 90 and 120 min of in vitro incubation with copper decreased significantly during the course of the study (Figure 3 ). For example, after 120 min of incubation with copper TBARS decreased from 66.3 AE 34 at inclusion to 39.1 AE 25.0 after 4 -6 days TPN (P ¼ 0.035) and to 42.2 AE 17.4 nmol MDA=mg LDL and VLDL cholesterol after 9 -11 days TPN. In group C there were no significant changes during the study. Thus the changes over time were significantly different in the two groups (P ¼ 0.022).
Although the lag time of fluorescence did not change significantly, the slope of the increase in fluorescence after . Open columns at inclusion; grey columns after 4 -6 days TPN; black columns after 9 -11 days TPN. Shown are mean values AE s.e.m. **P-value of < 0.01 when comparing the time-related changes in group E to the changes in group C. §P-value of < 0.05 when compared to the value at inclusion within each group.
a-Tocopherol supplementation in TPN
B Manuel-y-Keenoy et al the peroxidation process decreased in group E from 0.489 AE 0.173 FU=min at inclusion to 0.402 AE 0.097 after 9 -11 days of TPN. There were no significant changes in group C (P ¼ 0.026 for the between-groups comparison of the changes over time; Figure 2 ).
Discussion
Conventional intravenous soybean-oil based fat emulsions contain more than 50% n-6 PUFA in contrast to about 10% in an ordinary diet. Since this imbalance in fatty acids might cause increased lipid peroxidation and abnormal inflammatory responses, the search for alternative energy sources has focused on fats containing shorter chain fatty acids, such as for example, lipid emulsions containing MCTs. Substituting half of the soybean oil (source of the LCTs) by coconut oil (source of the MCTs) leads to halving the linoleic acid (18:2 n-6) content from 54 to 27% of the total fatty acid content. However, this also results in a decrease in a-tocopherol content from 12 to 6.5 mg=l emulsion. The potential antiperoxidative benefits of MCTs can therefore be masked by the decrease in antioxidant content. Since several authors have shown that supplementation with dosages such as those present in multivitamin formulas and which approach the RDA are insufficient to correct the a-tocopherol deficiency which appears during TPN (Kelly & Sutton, 1989) , we opted to supplement the LCT=MCT lipid emulsion with 100 mg DL-a-tocopherol daily. In this way, the patients in group E received 125 IU tocopherol daily in contrast to 20 IU in the group C. This lower dosage, which is compatible with the RDA, did not affect serum a-tocopherol levels nor lipoprotein peroxidation in vitro in this short-term study (11 days). In contrast, in group E serum a-tocopherol levels doubled and peroxidation in vitro decreased. There was a decrease in the production of TBARS (end products of PUFA peroxidation) and of fluorescent products (due to oxidative attack of TBARS on apoprotein B amino acids) when LDL and VLDL were incubated with copper in vitro. Although TBARS production was higher in the patients with higher cholesterol at inclusion, the improvement in peroxidation in group E was not associated with any changes in serum cholesterol. In contrast, triglyceride-glycerol increased in group E and Figure 2 Changes in serum a-tocopherol and lipid peroxidation during the course of the study. Lipid peroxidation in vitro was measured by incubating LDL and VLDL with copper and monitoring fluorescence continuously at 340=440 nm excitation=emission. Group E received Medialipide 1 supplemented with DL-a-tocopherol and group C received conventional Intralipid
1
. Open columns at inclusion, grey columns after 4 -6 days TPN; black columns after 9 -11 days TPN. Shown are mean values AE s.e.m. *P-value of < 0.05 and **P < 0.01 when comparing the time related changes in group E to the changes in group C. §P-value of < 0.05 and § §P < 0.01 when comparing to the value at inclusion within each group. a-Tocopherol supplementation in TPN B Manuel-y-Keenoy et al decreased in group C. These changes should be interpreted with care because emulsions containing the shorter chain fatty acids (group E) are richer in glycerol (1.57 mmol=g MCT-LCT) than pure LCT emulsions (1.14 mmol=g LCT). Moreover, the molar clearance rates of MCT=LCT and LCT infusions by hepatic and lipoprotein lipases have been shown to be similar (Nordenström et al, 1991; Treskova et al, 1999) . Thus our data cannot demonstrate any significant changes in serum triglycerides and suggest that the protection of the lipoprotein particles against peroxidation, at least that induced by copper in vitro, is determined by the increase in a-tocopherol relative rather than by any changes in serum cholesterol or triglycerides.
The other factors which have been described to affect lipoprotein peroxidation vary according to the type of patient and to the methodology used to measure peroxidation. For example, using our method, we have seen that TBARS production is mainly determined by triglycerides in type 1 diabetic patients (Zhang et al, 1994) but by LDLcholesterol and transferrin in patients with chronic fatigue (Manuel-y-Keenoy et al, 2001) . In this group of TPN patients, at inclusion, TBARS was related to LDL-cholesterol and lag time of fluorescence to serum a-tocopherol. Other authors have identified fatty acid composition, ubiquinol-10 and hydroperoxide content as factors which affect peroxidation more strongly than a-tocopherol content (Frei & Gaziano, 1993; Kontush et al, 1994) . Nevertheless, our results confirm that in this group of TPN patients, doubling serum a-tocopherol by giving extra supplements in the lipid emulsion was efficient in decreasing the susceptibility of their LDL and VLDL to peroxidation in vitro by about 40%. It should be emphasised here that the behaviour of lipoproteins in vitro does not necessarily mirror the in vivo situation for several reasons. First, the end-products monitored in the in vitro methods account for only a fraction of the PUFA consumed during the lipid peroxidation process, about 10% in the case of MDA (Esterbauer et al, 1991) . Second, factors in the microenvironment around the lipoprotein particle, such as vitamin C and bilirubin in plasma, can also influence the peroxidation process (Frei et al, 1988; Neuzil & Stocker, 1994) . In comparison to the numerous studies all demonstrating a beneficial effect of vitamin E supplementation on lipoprotein peroxidation in vitro (Simons et al, 1996) , the evidence on beneficial effects on peroxidation in vivo is still inconclusive and varies according to the type of peroxidation products being monitored. For example, vitamin E supplements during TPN had no effect on cholesterol oxidation products (Linseisen et al, 2000) . In normal subjects expired pentane decreased (Lemoyne et al, 1987) but TBARS in urine were unaffected when measured by HPLC (Kosugi et al, 1995) or decreased when measured by fluorometry (Cadenas et al, 1996) . In smokers, plasma TBARS and conjugated dienes decreased (Brown et al, 1994) , but in patients with congestive heart failure there was no effect on markers of oxidative stress (Keith et al, 2001 ). The impact of intervention studies on cardiovascular disease is even more controversial (Stephens et al, 1996; Heart Outcomes Prevention Evaluation Study Investigation, 2000) in spite of convincing epidemiological evidence on the protective role vitamin E intake on disease (Stampfer et al, 1993) .
Notwithstanding this still unresolved issue of the in vivo impact of vitamin E supplementation on cardiovascular disease, several considerations suggest that giving relatively high doses of a-tocopherol can be beneficial in TPN. They may be neccessary to combat the a-tocopherol deficiency which can appear during the course of TPN (Lemoyne et al, 1988) . It has also been shown in patients on long-term TPN that adequate a-tocopherol levels in plasma sometimes coexist with deficiencies in adipose tissue relative to cholesterol (Steephen et al, 1991) . This observation points to abnormalities in the exchange of tocopherols between blood and the tissues which might, in turn, be related to differences in blood lipid composition caused directly by the lipid emulsion itself and=or by the overall nutritional imbalance in these patients. Moreover, changes in lipoprotein composition, fat transport and rate of metabolisation leading to the persistence of the cholesterol-rich and protein-poor Lipoprotein X particles (Hajri et al, 1990) , as well as to imbalances in Figure 3 Time course of TBARS production during the in vitro incubation of LDL and VLDL lipoproteins with copper. TBARS production is expressed as nmol MDA equivalents=mg LDL-and VLDL-cholesterol. Shown are mean values AE s.e.m. §P-value of < 0.05 and § §P < 0.01 when comparing to the value at inclusion within each group. Open columns at inclusion; grey columns after 4 -6 days of TPN; and black columns after 9 -11 days of TPN.
a-Tocopherol supplementation in TPN B Manuel-y-Keenoy et al eicosanoid synthesis and release. All these abnormalities are conducive to increased lipid peroxidation in vivo (Endres, 1993) and might require higher serum a-tocopherol levels for efficient counteraction. However, several points need to be carefully considered and further investigated. First, the kinetics of vitamin E transport are different when absorbed orally or when given intravenously . When given orally, the alpha form is preferentially packed into the VLDL by the liver, so that more than 90% of the tocopherol in plasma is in the a form . Although some of the 'Intralipid' remnants are taken up by the liver and the a form is also preferentially packed into the VLDL (Steephen et al, 1991) , this is insufficient considering that only 8% of the tocopherols in the lipid emulsion are in the a form. Kelly found that after 2 weeks of TPN with Intralipid, the pattern of a, b and g tocopherols in plasma follows that of the Intralipid (Kelly & Sutton, 1989) .
Furthermore, although vitamin E has beneficial effects on neurological, membrane and immune functions (Meydani & Meydani, 1998) , and the dose given in this study is well within the absolutely safe range (Diplock, 1995) , the possible toxic effects of higher doses of vitamin E in the presence of clotting and inflammatory disorders which are often present in TPN patients, especially if suffering from sepsis, should be considered. For example, in septic guinea-pigs tripling the intake of vitamin E led to a decrease in mortality from 86 to 45% but increasing it nine-fold had no significant effect on the mortality (76%) (Peck & Alexander, 1991) .
Finally, the synergism of vitamin E with other antioxidants such as vitamin C, ubiquinol-10 and carotenoids as well as the antioxidant status of each patient should also be taken into account when deciding the doses of vitamin E to be administered during TPN.
In summary, this study demonstrates that supplementing TPN patients receiving MCT=LCT (50=50) with 100 mg=day of DL-a-tocopherol doubles serum a-tocopherol and decreases LDL and VLDL peroxidation in vitro.
